Anneli Elme

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao, Charles S. Fuchs, Kohei Shitara et al. · JAMA Oncology · 2021 · 443 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +12

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023 · 323 citations · Full text

Medicine, Oncology, Pharmacology +9

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · Gastric Cancer · 2021 · 166 citations · Full text

Medicine, Oncology, Pharmacology +11

Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments

Heidi Penttinen, Tiina Saarto, Pirkko Kellokumpu‐Lehtinen et al. · Psycho-Oncology · 2010 · 111 citations

Medicine, Oncology, Breast Oncology +15